

Supplementary material

Chrostowska P, Drozd-Sokołowska J, Miśkiewicz P. Erdheim-Chester disease with orbital involvement and progressive impairment of vision. *Pol Arch Intern Med.* 2022; 132: 16193. doi:10.20452/pamw.16193

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

| Table S1 Laboratory results | | |
|--|--------------|------------------------|
| Variable | Value | Reference range |
| C-reactive protein, mg/L | 24 | 0-10 |
| Ferritin, ng/ml | 447 | 30-400 |
| Iron, µg/dl | 67 | 37-158 |
| Sodium, mmol/L | 140 | 137-145 |
| Potassium, mmol/L | 4.75 | 3.6-5.0 |
| Chloride, mmol/L | 105 | 97-110 |
| Calcium, mmol/L | 2.34 | 2.15-2.60 |
| Phosphates, mmol/L | 1.39 | 0.81-1.45 |
| Magnesium, mmol/L | 0.94 | 0.75-1.00 |
| Red blood cell count, $\times 10^{12}/L$ | 5.00 | 4.20-5.70 |
| Hematocrit, % | 40.6 | 40.0-54.0 |
| Hemoglobin, g/dL | 14.3 | 14.0-18.0 |
| White cell count, $\times 10^9/L$ | 10.21 | 4.00-11.00 |
| Neutrophils, $\times 10^9/L$ | 7.14 | 1.9-8.0 |
| Eosinophils, $\times 10^9/L$ | 0.1 | 0.0-0.8 |
| Basophils, $\times 10^9/L$ | 0.05 | 0.0-0.2 |
| Lymphocytes, $\times 10^9/L$ | 1.7 | 0.9-5.2 |
| Monocytes, $\times 10^9/L$ | 1.1 | 0.16-1.00 |
| Platelets, $\times 10^9/L$ | 498 | 150-400 |
| Fibrinogen, mg/dL | 515 | 200-400 |
| Prothrombin time, s | 10.8 | |
| Activated partial thromboplastin time, s | 24.6 | 25.0-37.0 |
| D-dimer, ng/mL | 331 | 0-500 |
| Alanine aminotransferase, U/L | 12 | 7-56 |
| Aspartate aminotransferase, U/L | 9 | 5-40 |
| Total bilirubin, mg/dL | 0.35 | 0.20-1.20 |
| Creatinine, mg/dL | 0.88 | 0.50-1.10 |
| Glomerular filtration rate, ml/min | 107 | >60 |
| Uric acid, mg/dL | 4.5 | 2.8-7.0 |
| LDH, U/L | 143 | 135-225 |
| Albumin, g/dL | 3.9 | 3.5-5.3 |
| Total cholesterol, mg/dL | 218 | 120-190 |
| Low-density lipoprotein, mg/dL | 129 | |
| High-density lipoprotein, mg/dL | 46 | |
| Triglycerides, mg/dL | 215 | 50-150 |

| | | |
|---|---------------------------------|-------------|
| Thyrotropin, μ IU/mL | 1.170 | 0.270-4.200 |
| Free thyroxine, pmol/L | 15.3 | 12.0-22.0 |
| Free triiodothyronine, pmol/L | 4.59 | 3.1-6.8 |
| Thyrotropin receptor antibodies, IU/L | 0.87 | <1.75 |
| Anti-thyroid peroxidase antibodies, IU/mL | <9.0 | <34.0 |
| Anti-thyroglobulin antibodies, IU/mL | 10.7 | <115.0 |
| IgG4 subclass, g/L | 0.598 | 0.07-2.15 |
| Anti-neutrophil cytoplasmic antibodies | Not detected in the titer 1:10 | |
| Anti-nuclear antibodies | Not detected in the titer 1:100 | |
| Immunoglobulin A, mg/dL | 173 | 70-400 |
| Immunoglobulin M, mg/dL | 51 | 40-240 |
| Immunoglobulin E, IU/mL | 7.5 | <120 |
| Beta-2-microglobulin, mg/L | 2.16 | 0.9-2.0 |
| Monoclonal proteins in serum and urine | Not detected | |

Table S2 Due to cases of hypopituitarism in Erdheim-Chester disease, the hormonal function of the pituitary gland was assessed.

| Variable | Value | Reference range |
|--|-------|-----------------|
| Follicle-stimulating hormone, mIU/mL | 8.36 | 1.5-12.4 |
| Luteinizing hormone, mIU/mL | 5.21 | 1.7-8.6 |
| Testosterone, nmol/L | 13.10 | 8.64-29.00 |
| Estradiol, pg/mL | 25.7 | 11.3-43.2 |
| Prolactin, ng/mL | 11 | 4.04-15.2 |
| Adrenocorticotrophic hormone, pg/mL | 41.9 | 7.2-63.3 |
| Cortisol (8 a.m), μ g/dL | 13.5 | |
| Dehydroepiandrosterone sulfate, μ g/dL | 127.5 | 88.9-427.0 |
| Sex hormone binding globulin, nmol/L | 29.5 | 18.3-54.1 |

Table S3 Ophthalmological tests

| Variable | Right eye | Left eye | Reference range |
|---|-----------|----------|-----------------|
| V.a. before treatment | 0.4 | 1.0 | 1.0 |
| V.a. after methylprednisolone pulses | 0.7 | 1.0 | 1.0 |
| V.a. after treatment with cladribine | 0.8 | 1.0 | 1.0 |
| Proptosis before treatment, mm | 30 | 26 | <20 |
| Proptosis after treatment with cladribine (four months after the last dose), mm | 27 | 25 | <20 |
| Regurgitation of the eyelids before treatment, mm | 3 | 3 | - |
| Regurgitation of the eyelids after treatment, mm | 1 | 1 | - |

V.a. – visual acuity;